Bictegravir is a new integrase strand transfer inhibitor (INSTI) with a high genetic barrier to the development of HIV-1 resistance. The drug is co-formulated with the nucleos(t)ide reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide (AF) in a single-tablet regimen (STR) for the once-daily treatment of HIV-1 infection in adults (bictegravir/emtricitabine/tenofovir AF; Biktarvy
Adenine
Adult
Anti-HIV Agents
Dideoxynucleosides
Dose-Response Relationship, Drug
Drug Combinations
Emtricitabine
HIV Infections
Heterocyclic Compounds, 4 or More Rings
Humans
Lamivudine
Reverse Transcriptase Inhibitors
Treatment Outcome
